Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELABNASDAQ:PBMNASDAQ:PKBONASDAQ:PRFX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELABElevai Labs$2.26+1.8%$5.26$2.15▼$1,064.00$1.60M-1.23223,945 shs809,467 shsPBMPsyence Biomedical$0.55+19.0%$0.74$0.37▼$108.00$2.49M-0.13718,003 shs182,115 shsPKBOPeak Bio$0.02$0.05$0.00▼$0.26$520K1.758,940 shs66,140 shsPRFXPainReform$2.35+1.3%$2.56$1.68▼$23.27$2.06M0.721.41 million shs60,158 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELABElevai Labs-23.71%-14.62%-54.79%-89.77%-99.74%PBMPsyence Biomedical+1.14%+5.46%-23.67%-74.62%-99.23%PKBOPeak Bio0.00%0.00%0.00%0.00%+164.71%PRFXPainReform+0.87%+13.17%-9.73%-35.01%-32.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELABElevai Labs0.2294 of 5 stars0.03.00.00.00.60.00.6PBMPsyence BiomedicalN/AN/AN/AN/AN/AN/AN/AN/APKBOPeak BioN/AN/AN/AN/AN/AN/AN/AN/APRFXPainReform2.0764 of 5 stars3.05.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELABElevai Labs 0.00N/AN/AN/APBMPsyence Biomedical 0.00N/AN/AN/APKBOPeak Bio 0.00N/AN/AN/APRFXPainReform 2.00Hold$8.00240.43% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELABElevai Labs$2.45M0.65N/AN/A$44.17 per share0.05PBMPsyence BiomedicalN/AN/AN/AN/A($61.61) per shareN/APKBOPeak Bio$370K1.41N/AN/A($0.90) per share-0.03PRFXPainReformN/AN/AN/AN/A$111.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELABElevai Labs-$4.30M-$433.87N/A∞N/A-223.41%-124.93%-85.10%5/21/2025 (Estimated)PBMPsyence Biomedical-$51.16MN/A0.00∞N/AN/AN/AN/AN/APKBOPeak Bio-$12.83M-$0.16N/A∞N/AN/AN/A-179.31%N/APRFXPainReform-$9.34M-$147.33N/A∞N/AN/A-450.64%-241.33%5/21/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELABElevai LabsN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/APKBOPeak BioN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELABElevai Labs0.063.863.40PBMPsyence BiomedicalN/A0.640.64PKBOPeak BioN/A0.070.06PRFXPainReformN/A0.61N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELABElevai Labs22.22%PBMPsyence Biomedical77.44%PKBOPeak BioN/APRFXPainReform37.28%Insider OwnershipCompanyInsider OwnershipELABElevai Labs0.60%PBMPsyence Biomedical3.60%PKBOPeak Bio19.90%PRFXPainReform34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELABElevai Labs18707,0003.03 millionN/APBMPsyence BiomedicalN/A4.53 million6.36 millionN/APKBOPeak Bio323.13 million18.52 millionNot OptionablePRFXPainReform4875,00095,000Not OptionablePKBO, PBM, ELAB, and PRFX HeadlinesRecent News About These CompaniesPainReform Regains Nasdaq Compliance as of April 16, 2025April 17, 2025 | tipranks.comPainReform announces expansion into SEM sectorApril 10, 2025 | markets.businessinsider.comPainReform Shareholders Approve Key Proposals at April MeetingApril 10, 2025 | tipranks.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar’s AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | finance.yahoo.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | globenewswire.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | globenewswire.comPainReform Ltd: PainReform Provides Year-End Business UpdateApril 8, 2025 | finanznachrichten.dePainReform says shareholder equity now exceeds required thresholdApril 8, 2025 | markets.businessinsider.comPainReform Expands into Clean Energy with DeepSolar AcquisitionApril 7, 2025 | tipranks.comPainReform Provides Year-End Business UpdateApril 7, 2025 | globenewswire.comPainReform’s Shareholder Meeting Adjourned Due to Lack of QuorumApril 3, 2025 | tipranks.comPainReform acquires AI solar analytics firm DeepSolarMarch 7, 2025 | uk.investing.comPainReform Ltd: PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar AnalyticsMarch 5, 2025 | finanznachrichten.dePainReform completes acquisition of DeepSolarMarch 5, 2025 | markets.businessinsider.comPainReform Ltd. Completes Acquisition of DeepSolar, Expanding into Clean Energy SectorMarch 5, 2025 | quiverquant.comPainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar AnalyticsMarch 5, 2025 | globenewswire.comPainReform Ltd. Expands Share Offering to $4 MillionFebruary 26, 2025 | tipranks.comPainReform Ltd: PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion OpportunityFebruary 18, 2025 | finanznachrichten.deBladeranger divests Deepsolar to Painreform in strategic moveFebruary 18, 2025 | en.globes.co.ilPainReform stock soars on DeepSolar acquisitionFebruary 18, 2025 | au.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePKBO, PBM, ELAB, and PRFX Company DescriptionsElevai Labs NASDAQ:ELAB$2.26 +0.04 (+1.80%) Closing price 04:00 PM EasternExtended Trading$2.28 +0.02 (+0.66%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Psyence Biomedical NASDAQ:PBM$0.55 +0.09 (+19.00%) Closing price 03:59 PM EasternExtended Trading$0.55 +0.00 (+0.58%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.Peak Bio NASDAQ:PKBOPeak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.PainReform NASDAQ:PRFX$2.35 +0.03 (+1.29%) Closing price 03:59 PM EasternExtended Trading$2.35 0.00 (-0.21%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
